Literature DB >> 19225000

Role of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence.

Brenna Kelley-Clarke1, Erika De Leon-Vazquez, Katherine Slain, Andrew J Barbera, Kenneth M Kaye.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) LANA is an 1,162-amino-acid protein that tethers terminal repeat (TR) DNA to mitotic chromosomes to mediate episome persistence in dividing cells. C-terminal LANA self-associates to bind TR DNA. LANA contains independent N- and C-terminal chromosome binding regions. N-terminal LANA binds histones H2A/H2B to attach to chromosomes, and this binding is essential for episome persistence. We now investigate the role of C-terminal chromosome binding in LANA function. Alanine substitutions for LANA residues (1068)LKK(1070) and (1125)SHP(1127) severely impaired chromosome binding but did not reduce the other C-terminal LANA functions of self-association or DNA binding. The (1068)LKK(1070) and (1125)SHP(1127) substitutions did not reduce LANA's inhibition of RB1-induced growth arrest, transactivation of the CDK2 promoter, or C-terminal LANA's inhibition of p53 activation of the BAX promoter. When N-terminal LANA was wild type, the (1068)LKK(1070) and (1125)SHP(1127) substitutions also did not reduce LANA chromosome association or episome persistence. However, when N-terminal LANA binding to chromosomes was modestly diminished, the substitutions in (1068)LKK(1070) and (1125)SHP(1127) dramatically reduced both LANA chromosome association and episome persistence. These data suggest a model in which N- and C-terminal LANA cooperatively associates with chromosomes to mediate full-length LANA chromosome binding and viral persistence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225000      PMCID: PMC2668501          DOI: 10.1128/JVI.02395-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes.

Authors:  Jianxin You; Jennie L Croyle; Akiko Nishimura; Keiko Ozato; Peter M Howley
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

2.  Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding.

Authors:  Brenna Kelley-Clarke; Mary E Ballestas; Viswanathan Srinivasan; Andrew J Barbera; Takashi Komatsu; Te-Ana Harris; Mia Kazanjian; Kenneth M Kaye
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

3.  Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen.

Authors:  D Bubman; I Guasparri; E Cesarman
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

4.  Kaposi's sarcoma-associated herpesvirus LANA protein downregulates nuclear glycogen synthase kinase 3 activity and consequently blocks differentiation.

Authors:  Jianyong Liu; Heather Martin; Meir Shamay; Crystal Woodard; Qi-Qun Tang; S Diane Hayward
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

5.  Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program.

Authors:  Qiuhua Li; Fuchun Zhou; Fengchun Ye; Shou-Jiang Gao
Journal:  Virology       Date:  2008-08-05       Impact factor: 3.616

6.  Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.

Authors:  Joseph H Jeong; Joshua Orvis; Jong Wook Kim; Curtis P McMurtrey; Rolf Renne; Dirk P Dittmer
Journal:  J Biol Chem       Date:  2004-01-24       Impact factor: 5.157

7.  KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.

Authors:  Daniel L Di Bartolo; Mark Cannon; Yi-Fang Liu; Rolf Renne; Amy Chadburn; Chris Boshoff; Ethel Cesarman
Journal:  Blood       Date:  2008-01-16       Impact factor: 22.113

8.  The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc.

Authors:  Jianyong Liu; Heather J Martin; Gangling Liao; S Diane Hayward
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

9.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency.

Authors:  Ke Lan; Daniel A Kuppers; Subhash C Verma; Erle S Robertson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

Authors:  Grzegorz Sarek; Sari Kurki; Juulia Enbäck; Guergana Iotzova; Juergen Haas; Pirjo Laakkonen; Marikki Laiho; Päivi M Ojala
Journal:  J Clin Invest       Date:  2007-03-15       Impact factor: 14.808

View more
  28 in total

1.  Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen.

Authors:  Mel Campbell; Pei-Ching Chang; Steve Huerta; Chie Izumiya; Ryan Davis; Clifford G Tepper; Kevin Y Kim; Bogdan Shevchenko; Don-Hong Wang; Jae U Jung; Paul A Luciw; Hsing-Jien Kung; Yoshihiro Izumiya
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

Review 2.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

3.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Identification of Kaposi's sarcoma-associated herpesvirus LANA regions important for episome segregation, replication, and persistence.

Authors:  Erika De León Vázquez; Vincent J Carey; Kenneth M Kaye
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

Review 5.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen: Replicating and Shielding Viral DNA during Viral Persistence.

Authors:  Magdalena Weidner-Glunde; Giuseppe Mariggiò; Thomas F Schulz
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

6.  Effective formation of the segregation-competent complex determines successful partitioning of the bovine papillomavirus genome during cell division.

Authors:  Toomas Silla; Andres Männik; Mart Ustav
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

7.  A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.

Authors:  Crystal Woodard; Gangling Liao; C Rory Goodwin; Jianfei Hu; Zhi Xie; Thaila F Dos Reis; Rob Newman; Heesool Rho; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

8.  The Kaposi Sarcoma Herpesvirus Latency-associated Nuclear Antigen DNA Binding Domain Dorsal Positive Electrostatic Patch Facilitates DNA Replication and Episome Persistence.

Authors:  Shijun Li; Min Tan; Franceline Juillard; Rajesh Ponnusamy; Bruno Correia; J Pedro Simas; Maria A Carrondo; Colin E McVey; Kenneth M Kaye
Journal:  J Biol Chem       Date:  2015-09-29       Impact factor: 5.157

9.  H2AX phosphorylation is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome persistence.

Authors:  Hem Chandra Jha; Santosh Kumar Upadhyay; Mahadesh A J Prasad; Jie Lu; Qiliang Cai; Abhik Saha; Erle S Robertson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Murine gammaherpesvirus 68 LANA acts on terminal repeat DNA to mediate episome persistence.

Authors:  Aline C Habison; Chantal Beauchemin; J Pedro Simas; Edward J Usherwood; Kenneth M Kaye
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.